StreetInsider.com News Articles

Nutriband warrants to expire Sept. 30 at $6.43 strike price

Tue, 22 Sep 2026 08:02:49 -0400

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) confirmed that its outstanding warrants will expire on September 30, 2026, at 5 p.m. ET, with no extension or repricing of the terms.

There are currently 910,904 warrants outstanding at a strike price of $6.43 per share, representing $5,856,112 in potential proceeds to the company if all warrants are exercised before the deadline. Warrants not exercised by the expiration date will expire entirely and be removed from the Nasdaq listing under the ticker NTRBW.

Nutriband warrants to expire Sept. 30 at $6.43 strike price

Tue, 22 Sep 2026 08:02:49 -0400

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) confirmed that its outstanding warrants will expire on September 30, 2026, at 5 p.m. ET, with no extension or repricing of the terms.

Nutriband warrants to expire Sept. 30 at $6.43 strike price

Tue, 22 Sep 2026 08:02:49 -0400

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) confirmed that its outstanding warrants will expire on September 30, 2026, at 5 p.m. ET, with no extension or repricing of the terms.

Nutriband warrants to expire Sept. 30 at $6.43 strike price

Tue, 22 Sep 2026 08:02:49 -0400

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) confirmed that its outstanding warrants will expire on September 30, 2026, at 5 p.m. ET, with no extension or repricing of the terms.

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Tue, 22 Sep 2026 08:00:00 -0400

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants.

Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasdaq listing.

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Tue, 22 Sep 2026 08:00:00 -0400

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Tue, 22 Sep 2026 08:00:00 -0400

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Tue, 22 Sep 2026 08:00:00 -0400

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully

Form SCHEDULE 13D/A NutriBand Inc. Filed by: Sheridan Gareth

Tue, 15 Sep 2026 15:48:00 -0400

si-local-file:///var/storage/secattach/20260915/27064685.html

Nutriband CEO to attend Nasdaq LaB Biotech Summit in New York

Wed, 09 Sep 2026 09:20:11 -0400

Nutriband Inc. (NASDAQ: NTRB)(NASDAQ: NTRBW) announced that its chief executive officer, Gareth Sheridan, will attend the inaugural Nasdaq Life Sciences Advisory Board Biotech Summit on September 16 at Nasdaq MarketSite in New York.

The summit is described as bringing together biotechnology executives, investors, and industry leaders for networking and discussions.

Nutriband is a transdermal pharmaceutical company whose lead product in development is an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology, which embeds aversive agents into transdermal patches to deter abuse, misuse, and accidental exposure.

Nutriband CEO to attend Nasdaq LaB Biotech Summit in New York

Wed, 09 Sep 2026 09:20:11 -0400

The summit is described as bringing together biotechnology executives, investors, and industry leaders for networking and discussions.

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Wed, 09 Sep 2026 09:20:00 -0400

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Wed, 09 Sep 2026 09:20:00 -0400

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Wed, 09 Sep 2026 09:20:00 -0400

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Wed, 09 Sep 2026 09:20:00 -0400

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband gets USPTO publication notice for fentanyl patch trademarks

Tue, 08 Sep 2026 09:00:48 -0400

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) announced it has received a Notice of Publication from the United States Patent and Trademark Office (USPTO), dated September 2, 2026, for commercial brand name trademarks related to its abuse-deterrent fentanyl transdermal system.

The trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed within the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance. Once allowed, Nutriband plans to submit the commercial brand name to the FDA and other international regulatory agencies for review and approval.

The product is based on the company's AVERSA™ transdermal technology,

Nutriband gets USPTO publication notice for fentanyl patch trademarks

Tue, 08 Sep 2026 09:00:48 -0400

The product is based on the company's AVERSA™ transdermal technology,

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Tue, 08 Sep 2026 09:00:00 -0400

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system.

Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) dated September 2,

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Tue, 08 Sep 2026 09:00:00 -0400

Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Tue, 08 Sep 2026 09:00:00 -0400

Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Tue, 08 Sep 2026 09:00:00 -0400

Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Thu, 13 Aug 2026 07:00:00 -0400

ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26^th as part of the CEO spotlight event.

The Georgia Life Sciences Summit brings together leaders from across biotechnology, medical technology, research, manufacturing, and investment to showcase Georgia’s emergence as a national leader in life sciences innovation.

The Summit takes place on Aug 25-26 at the Sandy Springs Performing Arts Centre located at 1 Galambos Way, Sandy Springs, Georgia.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Thu, 13 Aug 2026 07:00:00 -0400

The Summit takes place on Aug 25-26 at the Sandy Springs Performing Arts Centre located at 1 Galambos Way, Sandy Springs, Georgia.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Thu, 13 Aug 2026 07:00:00 -0400

The Summit takes place on Aug 25-26 at the Sandy Springs Performing Arts Centre located at 1 Galambos Way, Sandy Springs, Georgia.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Thu, 13 Aug 2026 07:00:00 -0400

The Summit takes place on Aug 25-26 at the Sandy Springs Performing Arts Centre located at 1 Galambos Way, Sandy Springs, Georgia.

About AVERSA™ Abuse-Deterrent Transdermal Technology